熱門資訊> 正文
GRAIL专注于多种癌症早期检测;裁员30%
2024-08-14 05:19
- After Tuesday's closing bell, GRAIL (NASDAQ:GRAL) said it would focus its resources going forward on its core multi-cancer early detection programs, resulting in a 30% reduction in headcount.
- In addition, investment in programs outside its Galleri early cancer detection test will be greatly reduced.
- The cost reductions are projected to extend the company's existing cash runway from H2 2026 into 2028. Also, cash burn in 2025 is expected to lower to $325M.
-
GRAIL also reported its
first quarterly financial results as a standalone company following its
June spin-off from Illumina (
ILMN).
-
Revenue in Q2 was $32M, a 43% year-over-year increase. Its gross loss was -$17.9M, while non-GAAP adjusted gross profit was $16M.
-
The stock is
up ~3% in after-hours trading.
More on GRAIL, Inc.
- GRAIL: Ambitious Illumina Spin-Off Trading At Intriguing Valuation
- Grail to begin trading as Illumina completes spinoff
- Financial information for GRAIL, Inc.
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。